Feng Cong
Novartis (Switzerland)(CH)Novartis (China)(CN)First Affiliated Hospital of Heilongjiang University of Chinese Medicine(CN)Guangdong Laboratory Animals Monitoring Institute(CN)Tris Pharma (United States)(US)
Publications by Year
Research Areas
Wnt/β-catenin signaling in development and cancer, Cancer-related gene regulation, Peptidase Inhibition and Analysis, Chronic Myeloid Leukemia Treatments, Ubiquitin and proteasome pathways
Most-Cited Works
- → Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling(2009)2,068 cited
- → ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner(2012)960 cited
- → RNF146 is a poly(ADP-ribose)-directed E3 ligase that regulates axin degradation and Wnt signalling(2011)431 cited
- → Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma(2013)416 cited
- → The RSPO–LGR4/5–ZNRF3/RNF43 module controls liver zonation and size(2016)350 cited
- → Wnt signals across the plasma membrane to activate the β-catenin pathway by forming oligomers containing its receptors, Frizzled and LRP(2004)348 cited